Stock

Abivax S.A.

ABVX

Biotechnology · Healthcare

Also trades as: 0RA9.L GBP 0.79 (-4.90%) · ABVX.PA EUR 78.70 (-3.67%)

Price

$88.01

-2.22 (-2.46%)

Market Cap

$7.68B

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+349.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 15.5M (2021) → 69.5M (2025)

§Winston Score History

The full picture

Abivax is a French biotechnology company that develops drugs to treat chronic inflammatory diseases. Its lead drug candidate, obefazimod, is designed to treat conditions like ulcerative colitis — a painful disease of the large intestine that affects millions of people worldwide. The company focuses on patients who have not responded well to existing treatments.

Abivax earns no product revenue yet because obefazimod is still going through clinical trials and has not received regulatory approval. The company is headquartered in Paris but runs clinical programs across Europe and the United States, and it is listed on Nasdaq, giving it access to US capital markets. Its competitive position depends almost entirely on whether obefazimod succeeds in late-stage trials and wins approval from regulators like the FDA — a process that carries significant risk of failure, and the company continues to burn cash while awaiting those results.

Politician Trades

3 trades / 12mo

2 Congressional buys and 1 sell on ABVX in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

Reported EPS Growth

+7.5% YoY

Half-year reporting periods ended:

30 Jun 2025: €-1.59

30 Jun 2026: €-1.47

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

€178M/ year

↑ Rising (+21% vs prior year)

R&D investment increasing — building for the future

Insider Activity

8.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~2 years

€411M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-77.2%

Weak — -77.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.00

Conservative — low debt load (0.00)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial